Every 8-K that Oncotelic Therapeutics Inc (OTLC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OTLC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OTLC filings page.
Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP and issued a 2026 Pacific Pier Note 2, a convertible promissory note with aggregate gross principal of $178,410. The note bears 12% annual interest, includes a 12% original issue discount, and matures on the earlier of one year from the agreement date, acceleration upon an Event of Default, or full prepayment.
The note is convertible into common stock at the lesser of a fixed $0.06 per share Conversion Price or 85% of the lowest traded price over the ten trading days before conversion, with adjustment for certain corporate events. Oncotelic also issued 500,000 commitment shares to Pacific Pier. Prepayment is permitted at any time prior to six months from the note date with notice, and upon an Event of Default the amount becomes immediately due in cash with default interest of 16% per annum. The issuance relies on a Section 4(a)(2) Securities Act exemption.
Oncotelic Therapeutics, Inc. reports that on July 13, 2026 it delivered a corporate presentation to its employees, directors, officers and advisors. The presentation, referred to as the “Corporate Presentation,” is provided as Exhibit 99.1 to the current report.
The company states that the information furnished under Section 8.01, including Exhibit 99.1, is being furnished rather than filed for purposes of Section 18 of the Securities Exchange Act of 1934. It also clarifies that this information is not incorporated by reference into any Securities Act or Exchange Act filing, except where specifically referenced. The report is signed on behalf of the company by Vuong Trieu, Ph.D., its Chief Executive Officer.
Oncotelic Therapeutics, Inc. approved equity incentives for directors, officers, employees and advisors by granting an aggregate 17,796 restricted stock units (RSUs) under Restricted Stock Unit Award Agreements. Each RSU represents a contingent right to receive one share of Series A Convertible Preferred Stock, which is convertible into 1,000 shares of common stock.
The RSUs vest only if the company’s common stock is uplisted to a national stock exchange on or before June 30, 2027, or a later date if extended by the board, and the recipient continues service for six months after the uplisting. Otherwise, the RSUs automatically expire and are forfeited. Grants include 2,000 RSUs to CEO Vuong Trieu and 1,500 RSUs each to several senior executives. The awards are granted at no cost to recipients and rely on the private-offering exemption in Section 4(a)(2) of the Securities Act.
Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP and issued a convertible promissory note with an aggregate gross principal amount of $178,410. The note carries a 12% original issue discount, bears interest at 12% per year, and matures on the earlier of one year from the agreement date, an acceleration after an Event of Default, or full prepayment.
The note is convertible into common stock at the lower of a fixed $0.06 per share or 85% of the lowest traded price over the 10 trading days before conversion, subject to adjustments. Oncotelic also issued 500,000 shares of common stock to Pacific Pier as commitment shares. If an Event of Default occurs, the principal and accrued interest become immediately due in cash at a 16% default interest rate. The note and shares were issued in a private offering relying on the Section 4(a)(2) exemption from Securities Act registration.
Oncotelic Therapeutics, Inc. completed a patent-focused merger and related IP restructurings with Lunai Bioworks and affiliates. A holding company owning a multi‑jurisdictional patent portfolio was merged into a Lunai subsidiary, and Lunai issued eight shares of Series B Convertible Preferred Stock with an aggregate Stated Value of $20,000,000 to Oncotelic and Pelerin.
Oncotelic received five preferred shares with a stated value of $12,500,000 and a perpetual, royalty‑free, exclusive license to exploit the transferred intellectual property in all fields except defined biodefense and Alzheimer’s disease indications. Separately, Autotelic Inc. transferred additional drug and delivery platform assets to Oncotelic in exchange for equity equal to ten percent of Oncotelic’s fully diluted shares, issuable upon a future NYSE/NASDAQ uplisting. Both the merger consideration and the asset transfer were non‑cash transactions and rely on contracts attached as exhibits.
Oncotelic Therapeutics reported FY 2025 net income of about $249M, a sharp turnaround from a net loss of roughly $4.5M in 2024. Basic and diluted earnings were $0.59 per share versus a $0.01 loss per share a year earlier.
The swing was driven mainly by a non-cash gain of about $365.3M from revaluing its investment in joint venture GMP Biotechnology Limited, partly offset by a deferred income tax provision of about $111.6M. The company still reported no product revenue, and operating expenses were modest at roughly $3.2M.
Management highlighted progress across its GMP Bio JV, including six Deciparticle nanoparticle candidates, completion of a Phase 1 OT‑101/IL‑2 trial, a Phase 2/3 OT‑101 pancreatic cancer study, and expansion of its PDAOAI AI platform. They also referenced plans to pursue a potential Hong Kong IPO for the JV and a national exchange uplisting for Oncotelic.
Oncotelic Therapeutics entered a Joint Development, Manufacturing, and Licensing Agreement with TechForce Robotics on March 31, 2026 to co-develop AI-enabled, GMP-compliant robotic systems for pharmaceutical manufacturing. The product integrates TechForce’s robotic hardware with Oncotelic’s proprietary PDAOAI platform.
All AI-related foreground intellectual property and data generated by the product will be owned exclusively by Oncotelic, while TechForce owns its standalone hardware innovations and jointly developed IP is jointly owned. Commercial revenue terms, including revenue sharing and royalties, will be set later in a separate Commercialization and Licensing Agreement, and neither party may begin revenue-generating activities without mutual written consent.
The agreement uses project-based funding with milestone payments, allows either party to terminate for convenience on 60 days’ notice, and restricts TechForce for 12 months after termination from licensing the jointly developed IP for pharma manufacturing without Oncotelic’s approval. Oncotelic issued a press release on April 2, 2026 announcing the strategic partnership.
Oncotelic Therapeutics, Inc. reported that its minority-owned company Sapu Nano will introduce its Deciparticle™ nanomedicine platform and present its clinical pipeline at BIO-Europe Spring 2026 on March 25, 2026. Sapu Nano has been selected as a Presenting Company at the conference.
The session will feature Deciparticle, a sub-20 nm drug delivery platform designed to optimize tissue distribution, improve pharmacokinetics, and reduce formulation-related toxicities for hydrophobic oncology drugs. Two lead candidates include an intravenous everolimus formulation in Phase 1 clinical trials and an advanced docetaxel formulation entering Phase 1.
The disclosure also reiterates Oncotelic’s broader oncology strategy, including rare pediatric cancer designations through its 45% joint venture GMP Bio and programs such as OT-101, CA4P, OXi 4503, and AL-101 for neurological and sexual health indications, while emphasizing extensive forward-looking statement cautions.
Oncotelic Therapeutics, Inc. filed a current report describing a scientific disclosure rather than a financial event. The company announced that Sapu Nano, an entity in which it holds a minority interest, will present new everolimus toxicology data at the 2026 Society of Toxicology Annual Meeting and ToxExpo in San Diego. The poster, titled “Everolimus Toxicology: Tissue Concentration Effects,” examines how tissue-level exposure to everolimus relates to organ-specific toxic outcomes, extending understanding beyond traditional plasma pharmacokinetics. The work supports development of intravenous and nanoparticle-based formulations designed to better control drug distribution. The presentation is scheduled for March 23, 2026, during the ADME/Toxicokinetics I poster session.
Oncotelic Therapeutics, Inc. entered a Securities Purchase Agreement with Mast Hill Fund, LP and issued a secured convertible promissory note with an aggregate gross principal amount of $398,333.33. The note carries a 10% original issue discount, 10% annual interest and matures around one year after the agreement date, subject to earlier prepayment or default.
The note is convertible into common stock at a fixed price of $0.07 per share, subject to adjustment, and is secured by most company and subsidiary assets, excluding assets tied to its Dragon Overseas Capital joint venture. The company also issued 1,422,613 warrants with a $0.15 exercise price. Proceeds must be used for general working capital under specific restrictions. A registration rights agreement was signed to register shares underlying the note and warrants, which were issued under a private placement exemption.
Oncotelic Therapeutics approved a new milestone-based equity award for its CEO, Dr. Vuong Trieu, tied to improving the company’s capital structure. Under a restricted stock agreement, the company may issue up to 26,512 shares of Series A Preferred Stock, each convertible into 1,000 common shares, based on four specified financing and debt-related milestones. Dr. Trieu has already met the first milestone, earning 4,426 preferred shares, with the remaining 22,086 shares vesting in three equal tranches if additional milestones are achieved. The company states that the full award represents about 4.99% of common stock outstanding on the agreement date, with each milestone tranche equal to about 1.663% of common shares, subject to adjustment if the share count rises.
Oncotelic Therapeutics, Inc. disclosed that it amended an independent contractor agreement with Jefferson Capital Ventures, LLC and a restricted stock award agreement with its CEO, Dr. Vuong Trieu. Both arrangements grant stock awards upon achieving corporate milestones. The amendment lowers the first milestone trigger from a Company market capitalization exceeding $100 million on a single trading day’s close to $45 million on a single trading day’s close.
The company states this change is intended to help it continue building on its progress, including making effective its equity line with Mast Hills, engaging AGP for future financing, and working with Sichenzia, Ross and Ferrell on a potential uplisting of its stock to a nationally recognized exchange. All other terms and conditions of the milestone under Dr. Trieu’s restricted stock award remain unchanged.
Oncotelic Therapeutics, Inc. reported that it amended its independent contractor agreement with Jefferson Capital Ventures, LLC dated August 6, 2025. The change lowers the threshold for the first milestone that triggers restricted stock awards in Oncotelic common stock, reducing the required market capitalization level from $100 million on any single trading day’s close to $45 million on any single trading day’s close. The company states this amendment seeks to enable it to continue building on its progress, including making effective its equity line with Mast Hills, engaging AGP for future financing, and working with Sichenzia, Ross and Ferrell on a potential uplisting to a nationally recognized stock exchange. All other terms and conditions of the milestone remain unchanged.
Oncotelic Therapeutics, Inc. entered into subscription agreements for a third and final tranche of a private financing, issuing 44 units to 22 accredited investors on December 31, 2025. Each unit includes a $25,000 note bearing 12% annual interest and maturing two years after the final closing, along with warrants. The notes are convertible into up to 250,000 shares of Oncotelic common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc. common stock at $1.00 per share, both with anti-dilution protection. Each unit also carries 250,000 warrants to buy Oncotelic common stock at $0.12 or 25,000 warrants to buy EdgePoint stock at $1.25 per share.
This tranche completes an offering of up to 500 units conducted by Maker and includes an exchange of certain 2023 notes into the new notes, with related warrants extended by two years. The company also granted investors the ability to convert their EdgePoint shares into Oncotelic shares at the rate of 10 Oncotelic shares for each EdgePoint share. A registration rights agreement covers Oncotelic shares issued in the financing and issuable upon warrant exercise. The securities were issued as unregistered offerings under Regulation D.
Oncotelic Therapeutics, Inc. reported that on December 23, 2025 it entered into subscription agreements with 21 accredited investors for 32 financing units. Each unit includes a $25,000 note bearing 12% annual interest, maturing two years after the final closing of an offering of up to 500 units.
Each note can convert into up to 250,000 shares of Oncotelic common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc. common stock at $1.00 per share, with anti-dilution protections. Each unit also includes 250,000 warrants to buy Oncotelic stock at $0.12 or 25,000 EdgePoint warrants at $1.25 per share.
The company extended prior 2023 private placement warrants by two years and will treat the 2023 note as paid and rolled into the new notes. Investors may also convert their EdgePoint shares into Oncotelic stock at a rate of 10 Oncotelic shares for each EdgePoint share. Oncotelic granted registration rights for the common shares underlying the financing, relying on a Regulation D exemption from Securities Act registration.
Oncotelic Therapeutics, Inc. reported an operational update related to its data and AI strategy. The company announced via press release that it has opened access to PDAOAI, a proprietary evidence‑interrogation platform designed to pull biologically meaningful signals from large, complex biomedical datasets without training bespoke large language models on proprietary data. Oncotelic is also giving researchers access to a TGF-β literature corpus covering more than 125,000 PubMed abstracts through a dedicated Discord research channel, aiming to support discovery around this important biological pathway. The communication also reiterates that many statements about future plans, including joint venture activities, clinical development, token registration efforts and potential DAO-related initiatives, are forward-looking and subject to significant risks and uncertainties.
Oncotelic Therapeutics, Inc. entered into subscription agreements with accredited investors for 11 units in a private Offering of notes and warrants. Each unit includes a note with $25,000 principal, bearing 12% annual interest and maturing two years after the final closing of the Offering, plus warrants tied to Oncotelic or EdgePoint AI, Inc. shares at fixed conversion and exercise prices, subject to anti-dilution adjustments.
Investors in the company’s 2023 PPM notes can exchange their old notes for these new units, with prior warrants extended by two years and an option to convert EdgePoint shares into Oncotelic common stock at $0.10 per share. The company also granted registration rights for the Oncotelic shares underlying the notes and warrants. The securities were issued as unregistered securities under Section 4(a)(2) and Rule 506 of Regulation D.
Oncotelic Therapeutics (OTLC) furnished an investor presentation given by CEO Dr. Vuong Trieu at LD Micro in San Diego on October 21, 2025. The presentation, filed as Exhibit 99.1, includes forward-looking statements covering areas such as JV plans (including a potential IPO), clinical development timing and data reporting, regulatory approvals, the company’s nanoparticle platform, a planned DAO-based company, pet and animal health initiatives, and token-related registrations and tradability.
The materials are furnished under Item 8.01 and are not deemed “filed,” which limits their incorporation into other SEC filings.